AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9284426 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 8498759 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg methadone
Number of subjects: 247
Study 8498759 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methadone
Number of subjects: 247
Study 8498759 — intervention group
Group type: COMPARATOR
Intervention: 0 mg methadone (placebo)
Number of subjects: 247
Study 3561160 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg, iv.)
Number of subjects: 0
Study 3561160 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 0
Study 31046757 — intervention group
Group type: EXPERIMENTAL
Intervention: Internship only (I-Group, n=10)
Number of subjects: 44
Study 31046757 — intervention group
Group type: COMPARATOR
Intervention: Course only (C-Group, n=21)
Number of subjects: 44
Study 31046757 — intervention group
Group type: EXPERIMENTAL
Intervention: Course and internship (CI-Group, n=13)
Number of subjects: 44
Study 28624123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 140
Study 28624123 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 140
Study 24729068 — intervention group
Group type: EXPERIMENTAL
Intervention: Driven exercise (DE) in adolescents with anorexia nervosa (AN)
Number of subjects: 201
Study 24729068 — intervention group
Group type: EXPERIMENTAL
Intervention: Driven exercise (DE) in adolescents with bulimia nervosa (BN)
Number of subjects: 201
Study 23391031 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth‐811 sealer
Number of subjects: 80
Study 23391031 — intervention group
Group type: EXPERIMENTAL
Intervention: AH‐26 sealer
Number of subjects: 80
Study 23391031 — intervention group
Group type: EXPERIMENTAL
Intervention: Guttaflow sealer
Number of subjects: 80
Study 23391031 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany SE sealer
Number of subjects: 80
Study 23391031 — intervention group
Group type: COMPARATOR
Intervention: Control group (debrided only)
Number of subjects: 80
Study 21235477 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with D. pteronyssinus extract
Number of subjects: 45
Study 21235477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18155056 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia (2 mg morphine in 15 mL of 1% lidocaine)
Number of subjects: 40
Study 18155056 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline in 15 mL)
Number of subjects: 40
Study 16564436 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal reliving in cognitive therapy for PTSD
Number of subjects: 44
Study 15260199 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially organized mental map
Number of subjects: 0
Study 15260199 — intervention group
Group type: COMPARATOR
Intervention: Temporally organized mental map
Number of subjects: 0
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments completed by women
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term/recurrent pain incidence
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder/arm or lower back pain
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional/affective pain effects
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Limitations in daily occupations
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in pain prevalence
Number of subjects: 10000
Study 11197521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain variables, daily occupations, sick-leave, work variables
Number of subjects: 10000
Study 9088300 — intervention group
Group type: EXPERIMENTAL
Intervention: Labored breathing for 1 min
Number of subjects: 0
Study 9088300 — intervention group
Group type: EXPERIMENTAL
Intervention: Labored breathing for 30 min
Number of subjects: 0
Study 9088300 — intervention group
Group type: EXPERIMENTAL
Intervention: Labored breathing for twice 30 min (with a 30‐min interval in between)
Number of subjects: 0
Study 8392957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (0.8-1.0 g daily)
Number of subjects: 27
Study 8392957 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (3 MU three times weekly)
Number of subjects: 27
Study 8392957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ribavirin and interferon beta
Number of subjects: 27
Study 3486641 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis
Number of subjects: 71
Study 3486641 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 71
Study 30932360 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 351
Study 30932360 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 351
Study 30091688 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSAE‐Stress‐Prosocial (ESPS) intervention
Number of subjects: 183
Study 30091688 — intervention group
Group type: COMPARATOR
Intervention: Social Study curriculum (SS) active control group
Number of subjects: 183
Study 27198539 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia crowns
Number of subjects: 20
Study 27198539 — intervention group
Group type: COMPARATOR
Intervention: Contralateral natural antagonists (control teeth)
Number of subjects: 20
Study 27198539 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 20
Study 24469600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg) with Korean traditional food
Number of subjects: 0
Study 24469600 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride (50 mg) under fasting state
Number of subjects: 0
Study 22241786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clarithromycin 500 mg/bid for 2 weeks and then 250 mg/d for 6 weeks
Number of subjects: 32
Study 22241786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mometasone furoate 200 mcg/d for 8 weeks added to clarithromycin regimen
Number of subjects: 32
Study 22241786 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 32
Study 21084905 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-multidetector-row computed tomography with a bolus-tracking program, scan delay of 10 to 19 seconds
Number of subjects: 120
Study 21084905 — intervention group
Group type: COMPARATOR
Intervention: 5-second arterial phase
Number of subjects: 120
Study 21084905 — intervention group
Group type: COMPARATOR
Intervention: 15-second arterial phase
Number of subjects: 120
Study 19055205 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 678
Study 19055205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study 15878583 — intervention group
Group type: EXPERIMENTAL
Intervention: MSA-P
Number of subjects: 106
Study 15878583 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 106
Study 15878583 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study 12789263 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Number of subjects: 75
Study 12789263 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine/cisplatin
Number of subjects: 75
Study 12789263 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin
Number of subjects: 75
Study 11393462 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to exaggerate problems
Number of subjects: 118
Study 11393462 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to feign a disorder
Number of subjects: 118
Study 11393462 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to feign global psychological disturbance
Number of subjects: 118
Study 11393462 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard instructions)
Number of subjects: 118
Study 11393462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissimulation Scale (Ds2)
Number of subjects: 118
Study 9235556 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 11
Study 9235556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7962428 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile women (unexplained infertility)
Number of subjects: 15
Study 7962428 — intervention group
Group type: COMPARATOR
Intervention: Fertile women (control group)
Number of subjects: 15
Study 3653498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mg three times a day)
Number of subjects: 33
Study 3653498 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg three times a day)
Number of subjects: 33
Study 3653498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29310868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity nasal insufflation
Number of subjects: 204
Study 29310868 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 204
Study 27687359 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo, group C)
Number of subjects: 200
Study 27687359 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.4mg/kg (group Me)
Number of subjects: 200
Study 27687359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25mg/kg plus midazolam 37.5μg/kg (group KMi)
Number of subjects: 200
Study 27687359 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.2mg/kg plus dexamethasone 0.1mg/kg (group MeD)
Number of subjects: 200
Study 25558561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dilator technique (Group I)
Number of subjects: 16
Study 25558561 — intervention group
Group type: COMPARATOR
Intervention: Single dilator technique (Group II)
Number of subjects: 16
Study 25558561 — intervention group
Group type: COMPARATOR
Intervention: Forceps dilator technique (Group III)
Number of subjects: 16
Study 25558561 — intervention group
Group type: COMPARATOR
Intervention: Twist dilator technique (Group IV)
Number of subjects: 16
Study 22399275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g CMC-001
Number of subjects: 32
Study 22399275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g CMC-001
Number of subjects: 32
Study 22399275 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g CMC-001
Number of subjects: 32
Study 20736989 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4 μg/kg)
Number of subjects: 52
Study 20736989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18272538 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) with external liaisons (liaison schools, LS)
Number of subjects: 515
Study 18272538 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) with internal champions (champion schools, CS)
Number of subjects: 515
Study 18272538 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 515
Study 16501947 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled SIMV
Number of subjects: 15
Study 16501947 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled SIMV
Number of subjects: 15
Study 12520624 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 0.5 mg
Number of subjects: 27
Study 12520624 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1.0 mg
Number of subjects: 27
Study 12520624 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 2.0 mg
Number of subjects: 27
Study 12520624 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 11349506 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (for normotensive patients)
Number of subjects: 100
Study 11349506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for normotensive patients)
Number of subjects: 100
Study 11349506 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (for hypertensive patients)
Number of subjects: 100
Study 11349506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (for hypertensive patients)
Number of subjects: 100
Study 8861673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxia (HYP) during exercise
Number of subjects: 14
Study 8861673 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NORM) during exercise
Number of subjects: 14
Study 1519617 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent-exposed workers
Number of subjects: 234
Study 1519617 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 234
Study 30044209 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation
Number of subjects: 22
Study 30044209 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 28899680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritive sweetener (sucrose)
Number of subjects: 64
Study 28899680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener (sucralose)
Number of subjects: 64
Study 28899680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose in solid form
Number of subjects: 64
Study 28899680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose and sucrose exposure
Number of subjects: 64
Study 28899680 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food form
Number of subjects: 64
Study 28899680 — intervention group
Group type: COMPARATOR
Intervention: Learning effect
Number of subjects: 64
Study 25863562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 (four doses of 2.5 mg at weeks 0, 2, 4, and 6)
Number of subjects: 247
Study 25863562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 25863562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3
Number of subjects: 247
Study 25863562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 and Placebo
Number of subjects: 247
Study 24618443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pancreatic enzyme supplementation
Number of subjects: 56
Study 24618443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22811032 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐intensity exercise training and dietary modification (3 d·wk for up to 55 min per session at 50%‐60% V˙O2peak) for 48 weeks
Number of subjects: 21
Study 22811032 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard of care, instructed not to start a structured exercise program)
Number of subjects: 21
Study 21091294 — intervention group
Group type: EXPERIMENTAL
Intervention: Trataka (yogic visual concentration practice)
Number of subjects: 30
Study 21091294 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 30
Study 17473086 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition A (standard serving: 1 large serving at a single time point)
Number of subjects: 18
Study 17473086 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition B (portioning: 4 smaller servings presented at a single time point)
Number of subjects: 18
Study 17473086 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition C (portioning and eating rate: 4 smaller servings presented at 15-minute intervals)
Number of subjects: 18
Study 15868655 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 5 mg/day
Number of subjects: 54
Study 15868655 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 10 mg/day
Number of subjects: 54
Study 15868655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical sample
Number of subjects: 260
Study 12117626 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (severity of depression, younger age, personality symptoms)
Number of subjects: 260
Study 9585778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 mcg/kg beginning 1 hour before arteriography and continuing for 12 hours
Number of subjects: 55
Study 9585778 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 55
Study 7639166 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 49
Study 7639166 — intervention group
Group type: COMPARATOR
Intervention: Right heart catheterization
Number of subjects: 49
Study 11534531 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade therapy
Number of subjects: 600
Study 11534531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 662085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml
Number of subjects: 20
Study 662085 — intervention group
Group type: COMPARATOR
Intervention: Isopaque Cerebral 280 mg I/ml
Number of subjects: 20
Study 662085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml (selective external carotid injection)
Number of subjects: 20
Study 662085 — intervention group
Group type: COMPARATOR
Intervention: Isopaque (selective external carotid injection)
Number of subjects: 20
Study 31420389 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 162
Study 31420389 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression)
Number of subjects: 162
Study 29072432 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Number of subjects: 108
Study 29072432 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Number of subjects: 108
Study 29072432 — intervention group
Group type: COMPARATOR
Intervention: 7-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Number of subjects: 108
Study 29072432 — intervention group
Group type: COMPARATOR
Intervention: 14-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Number of subjects: 108
Study 25735205 — intervention group
Group type: EXPERIMENTAL
Intervention: Original digitally recorded speech tokens
Number of subjects: 10
Study 25735205 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally processed speech tokens emphasizing transient components
Number of subjects: 10
Study 25735205 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally processed speech tokens emphasizing quasi-steady-state components
Number of subjects: 10
Study 22819747 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious gaming (active distraction)
Number of subjects: 60
Study 22819747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lollipops (passive distraction)
Number of subjects: 60
Study 22819747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22136848 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH suppressive therapy (group A)
Number of subjects: 271
Study 22136848 — intervention group
Group type: COMPARATOR
Intervention: No therapy (group B)
Number of subjects: 271
Study 19369462 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus MTX
Number of subjects: 678
Study 19369462 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 678
Study 19369462 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 678
Study 16443858 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide 30 mg
Number of subjects: 15
Study 16443858 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide 1.25 mg
Number of subjects: 15
Study 16443858 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 15322439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiology education
Number of subjects: 0
Study 15322439 — intervention group
Group type: COMPARATOR
Intervention: Back anatomy and physiology education (Control)
Number of subjects: 0
Study 11029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg with each meal, three times per day for 2.5 days)
Number of subjects: 22
Study 9071623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg single dose of ketoconazole (Regimen A)
Number of subjects: 120
Study 9071623 — intervention group
Group type: COMPARATOR
Intervention: 200 mg daily dose of ketoconazole for 10 days (Regimen B)
Number of subjects: 120
Study 7871052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (low dose intravenous infusion for up to 2 weeks)
Number of subjects: 9
Study 7871052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (blinded, placebo-controlled, individualized optimal dosing for 5 days)
Number of subjects: 9
Study 7871052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during blinded, placebo-controlled phase)
Number of subjects: 9
Study 3518547 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (3 X 200 mg tablets daily with meals)
Number of subjects: 118
Study 3518547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets daily)
Number of subjects: 118
Study 30206267 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral TXA 2 hours preoperatively
Number of subjects: 180
Study 30206267 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg/kg IV TXA 5 minutes prior to incision
Number of subjects: 180
Study 30206267 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g IA TXA
Number of subjects: 180
Study 26471977 — intervention group
Group type: EXPERIMENTAL
Intervention: Müller straight stem (MSS)
Number of subjects: 646
Study 26471977 — intervention group
Group type: COMPARATOR
Intervention: Virtec straight stem (VSS)
Number of subjects: 646
Study 25666427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CDDP (810 mg)
Number of subjects: 223
Study 25666427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose CDDP (540 mg)
Number of subjects: 223
Study 25666427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 23434737 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (20, 40, or 80 μg of truncated glycoprotein D from HSV-2 strain)
Number of subjects: 150
Study 23434737 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different aluminum salts: AlPO₄ or Al(OH)₃)
Number of subjects: 150